Inert and stable radiolabeling of monoclonal antibodies (mAb), antibody fragments, or antibody mimetics with radiometals is a prerequisite for immuno-PET. While radiolabeling is preferably fast, mild, efficient, and reproducible, especially when applied for human use in a current Good Manufacturing Practice compliant way, it is crucial that the obtained radioimmunoconjugate is stable and shows preserved immunoreactivity and in vivo behavior. Radiometals and chelators have extensively been evaluated to come to the most ideal radiometal-chelator pair for each type of antibody derivative. Although PET imaging of antibodies is a relatively recent tool, applications with 89Zr, 64Cu, and 68Ga have greatly increased in recent years, especially in ...
The successful clinical application of targeted-radiopharmaceuticals depends on the development of m...
Radioimmunotherapy (RIT) delivers radioisotopes to antigen expressing cells via monoantibodies for t...
Absorbed doses in 90Y radioimmunotherapy are usually estimated by extrapolating from 111In imaging d...
The development of novel bioconjugates; antibodies, antibody mimetics and peptides is revolutionisin...
The use of fluorine-18 as a radionuclide for positron emission tomography (PET) has become increasin...
Purpose: Monoclonal antibodies (MAbs) labelled with 124I are an attractive option for quantitative i...
Presently, hundreds of monoclonal antibodies (mAbs) and mAb fragments are under clinical development...
Abstract During the past decade, the efficacy of new molecular targeted drugs such as monoclonal ant...
Radiometals are becoming increasingly accessible and are utilized frequently in the design of radiot...
In theranostics, radiolabeled compounds are used to determine a treatment strategy by combining ther...
Monoclonal antibodies (mAbs), immunoglobulin fragments, and other proteins are important scaffolds i...
This paper reviews some aspects and recent developments in the use of antibodies to target radionucl...
Our previous studies on the preparation of 186Re-MAb conjugates for clinical radioimmunotherapy (RIT...
The most widely cited procedures for radiolabeling antibodies with zirconium-89 for immuno-PET requi...
A detailed technical protocol is provided for reproducible and aseptical production of stable 186Re-...
The successful clinical application of targeted-radiopharmaceuticals depends on the development of m...
Radioimmunotherapy (RIT) delivers radioisotopes to antigen expressing cells via monoantibodies for t...
Absorbed doses in 90Y radioimmunotherapy are usually estimated by extrapolating from 111In imaging d...
The development of novel bioconjugates; antibodies, antibody mimetics and peptides is revolutionisin...
The use of fluorine-18 as a radionuclide for positron emission tomography (PET) has become increasin...
Purpose: Monoclonal antibodies (MAbs) labelled with 124I are an attractive option for quantitative i...
Presently, hundreds of monoclonal antibodies (mAbs) and mAb fragments are under clinical development...
Abstract During the past decade, the efficacy of new molecular targeted drugs such as monoclonal ant...
Radiometals are becoming increasingly accessible and are utilized frequently in the design of radiot...
In theranostics, radiolabeled compounds are used to determine a treatment strategy by combining ther...
Monoclonal antibodies (mAbs), immunoglobulin fragments, and other proteins are important scaffolds i...
This paper reviews some aspects and recent developments in the use of antibodies to target radionucl...
Our previous studies on the preparation of 186Re-MAb conjugates for clinical radioimmunotherapy (RIT...
The most widely cited procedures for radiolabeling antibodies with zirconium-89 for immuno-PET requi...
A detailed technical protocol is provided for reproducible and aseptical production of stable 186Re-...
The successful clinical application of targeted-radiopharmaceuticals depends on the development of m...
Radioimmunotherapy (RIT) delivers radioisotopes to antigen expressing cells via monoantibodies for t...
Absorbed doses in 90Y radioimmunotherapy are usually estimated by extrapolating from 111In imaging d...